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Since the CD40 ligand is also cleaved off from the mem-
brane to become soluble, it is likely that all TNF family
members are processed to a soluble form. The solubleIntroduction
form of human FasL is functional, but mouse FasL loses
its activity when it is cleaved from the membrane. Fur-There is an old Japanese saying that “Once we are in
thermore, membrane-bound TNF is more active thanthe land of the living, we will eventually die.” This is true,
soluble TNF in activating the type II TNF receptor (Grellnot only for human beings, but also for the cells that
et al., 1995). These results may indicate that FasL andconstitute our bodies. By repeated cell division (mitosis)
TNF work locally via cell–cell interactions under physio-and differentiation, a fertilized egg produces billions of
logical conditions and that the purpose of shedding TNFcells to create our bodies. During this process, many
or FasL is to attenuate the process.surplus or harmful cells are generated, and they must
The functional, soluble forms of TNFs as well as hu-be removed or killed (Jacobson et al., 1997 [this issue
man FasL exist as trimers (Tanaka et al., 1997). It hasof Cell]. For example, thymocytes that have failed to
not yet been demonstrated whether membrane-boundrearrange their T cell–receptor gene, or whose T cell
TNF or FasL are trimers. However, lymphotoxin b, areceptor may recognize their own tissues, must be elimi-
member of the TNF family, consists of a heterotrimernated. The magnitude of the cell death is staggering:
of one a (lymphotoxin-a, or TNFb) and two b chains
more than 95% of thymocytes die in the thymus during
(lymphotoxin-b) on the membrane (Androlewicz et al.,
maturation. Even in adults, senescent cells are removed
1992), suggesting that membrane-bound TNF and FasL
and replaced by newly generated cells to maintain ho-
have the potential to form trimeric structures. X-ray
meostasis. The cell death that occurs during em-
diffraction analyses of TNFa and TNFb have indicated
bryogenesis, metamorphosis, endocrine-dependent tis-
that each monomer forms an elongated, antiparallel
sue atrophy, and normal tissue turnover is “programmed
b-pleated sheet sandwich with a jelly roll topology
cell death,” mediated by a process termed “apoptosis.”
(Jones et al., 1989). Amino acids conserved among
Here, I focus on apoptosis controlled by cytokines.
members of the TNF family are mainly within the b
Two death factors, Fas ligand (FasL) or tumor necrosis
strands. Computer-assisted modeling of FasL based on
factor (TNF), bind to their receptors and induce
the amino acid sequence suggests that FasL has a simi-
apoptosis, killing the cells within hours. In a classic defi- lar tertiary structure to TNFa and TNFb.
nition of apoptosis, cells die by “suicide;” that is, cells The Fas and TNF Receptor Family
programmed to die would do so autonomously. How- Fas (also known as APO-1 or CD95), the receptor for
ever, the identification of death factor–receptor pairs FasL, is a type I–membrane protein (Itoh et al., 1991;
that regulate apoptosis indicates that apoptosis can Oehm et al., 1992) and a member of the TNF receptor
also becontrolled by an external killer in someinstances. (TNFR) family, which includes two TNFRs (TNFR1 and
TNFR2), the receptor for lymphotoxin-b, the NGF recep-
Death Factor and Receptor tor (p75), CD40, CD27, and CD30 (Nagata and Golstein,
Fas Ligand and the TNF Family 1995). This family is still growing, and three new mem-
Cytokines are a family of proteins that regulate cellular bers have recently been identified. They are human DR-3
proliferation and differentiation by binding to their spe- (death receptor-3)/Wsl-1 (Chinnaiyan et al., 1996; Kiston
cific receptors on target cells. Cytokines are grouped et al., 1996), human HVEM (herpes virus early mediator)
into at least three subfamilies based on structure, cyste- (Montogomery et al., 1996), and chicken CAR1 (cyto-
ine-knot growth factors, tumor necrosis factor, and heli- pathic avian leukosis-sarcoma virus receptor) (Brojatsch
cal cytokines. FasL belongs to the TNF family (Suda et et al., 1996). The extracellular region of the TNF receptor
al., 1993; Nagata and Golstein, 1995), which includes family members carries 2–6 repeats of a cysteine-rich
TNF, lymphotoxin, CD30 ligand, 4-1BB ligand, CD40 subdomain that has about 25% similarity among various
ligand, CD27 ligand, and TRAIL (TNF-related apoptosis- members. In contrast, the cytoplasmic regions have little
inducing ligand). FasL is synthesized as a type II–mem- similarity among the members, except for Fas, TNFR1,
brane protein; that is, its N terminus is in the cytoplasm DR-3/Wsl-1, and CAR1, as discussed below.
and its C-terminal region extends into the extracellular TNF induces apoptosis and activates the transcription
space. The extracellular region of about 150 amino acids factor NF-kB. It can also stimulate the proliferation of
thymocytes. Although both TNFR1 and TNFR2 canis well conserved (20–25%) among members of the TNF
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transduce the signal for apoptosis and NF-kB activation, Fas- and TNFR1-mediated apoptosis occur in the
TNFR1 is responsible for these signals in most cases presence of inhibitors of either RNA or protein synthesis
(Vandenabeele et al., 1995). On the other hand, TNFR2 (Yonehara et al., 1989; Itoh et al., 1991). Even enucleated
but not TNFR1 is responsible for the TNF-induced prolif- cells undergo apoptosis upon Fas activation (Schulze-
eration signal in thymocytes. Binding of FasL to Fas or Osthoff et al., 1994), suggesting that all of the compo-
cross-linking Fas with agonistic antibodies (IgM class nents necessary for apoptotic signal transduction are
anti-Fas antibody, or IgG3 class anti-APO1 antibody) present and that Fas activation simply triggers this ma-
induces apoptosis in Fas-bearing cells (Trauth et al., chinery. To dissect the signal-transducing machinery for
1989; Yonehara et al., 1989; Itoh et al., 1991). Most other Fas- and TNFR1-mediated apoptosis, two approaches
receptors in the TNF receptor family transduce activa- have been used. In one approach, several groups have
tion or stimulatory signals, although some of them, such identified a molecule(s) that binds to the cytoplasmic
as CD40 and CD30, may also have the ability to inhibit region of Fas or TNFR1, while in the other, information
growth, probably causing apoptosis. The presence of gained from studying apoptosis in the nematode, C.
a homologous domain (about 80 amino acids) in the elegans, was applied to the Fas and TNF system.
cytoplasmic regions of Fas and TNFR1 suggested that Utilization of the yeast two-hybrid system with the Fas
this region is responsible for transducing the death sig- cytoplasmic region as bait led to the identification of
nal. In fact, subsequent mutational analyses in Fas and a molecule called FADD (Fas-associating protein with
TNFR1 indicated that this is the case, and this domain death domain) or MORT1, which contains a death do-
has been designated a death domain (Itoh and Nagata, main at its C terminus (Boldin et al., 1995; Chinnaiyan
1993; Tartaglia et al., 1993). DR-3/Wsl-1 also carries a et al., 1995). FADD/MORT1 is recruited to Fas upon its
death domain and has the potential to transduce an activation (Kischkel et al., 1995) and binds to Fas via
apoptotic signal, as well as to activate NF-kB (Chinnai- interactions between the death domains. The N-terminal
yan et al., 1996; Kiston et al., 1996). CAR1, which also region (termed the death effector domain [DED] or
contains a death domain, has been shown to cause MORT1 domain) is responsible for downstream signal
apoptosis in chicken cells when it is cross-linked by the transduction. A similar death domain–containing protein
envelope protein of ALSV (Brojatsch et al., 1996). (TRADD, TNFR1-associated death domain protein)
The death domain has a tendency to self-aggregate,
binds to TNFR1 (Hsu et al., 1995). But unlike FADD/
and the tertiary structure of the Fas death domain, re-
MORT1, TRADD does not carry a death effector domain,
vealed by heteronuclear multidimensional NMR spec-
and its death domain is responsible for mediating
troscopy, shows that the death domain is a novel protein
apoptosis. This apparent discrepancy between FADD/
fold consisting of six antiparallel, amphipathic a helices
MORT1 and TRADD is resolved by the finding that
(Huang et al., 1996). Many charged amino acids are
TRADD binds to FADD/MORT1 via interactions betweenpresent on the surface, which is probably responsible
their death domains (Hsu et al., 1996b). These resultsfor mediating the interactions between death domains
suggest that Fas and TNFR1 use FADD as a commondescribed below.
signal transducer and share the signaling machinery
downstream of FADD/MORT1 (Figure 1). In addition toSignal for Apoptosis
this pathway, TNFR1 has another pathway leading toCascade Leading to ICE
apoptosis. RIP (receptor interacting protein), originallyBinding of ligand to a tyrosine kinase receptor, such
identified as a Fas-binding protein, preferentially bindsas PDGF or EGF receptor, induces dimerization of the
to TRADD (Hsu et al., 1996a). RIP is a serine/threoninereceptor and activates the intrinsic kinase activity in the
kinase containing a death domain and binds to TRADDcytoplasmic domain. The receptors for hematopoietic
via interactions between their death domains. RIP in-growth factors such as colony-stimulating factor and
duces apoptosis when overexpressed. The death do-for interferons do not contain kinase domains in their
main of RIP, but not its kinase domain, is responsiblecytoplasmic regions. Instead, the ligand-induced dimer-
for transduction of the death signal, indicating that RIPization recruits a kinase(s) to the receptor and activates
does not possess a death effector domain, but ratherit, which then results in transduction of the proliferation
another downstream effector molecule may be recruitedand/or differentiation signals. In the case of Fas or
through the death domain of RIP (see below) (Figure 1).TNFR1, however, dimerization with a divalent anti-Fas or
To find the signaling molecule downstream of FADD/TNFR1 monoclonal antibody is not sufficient to activate
MORT1, Wallach and his associates again used thethese receptors. Fas and TNFR1 must be oligomerized
yeast two-hybrid system, using the N-terminal DED/to be activated; that is, IgM class anti-Fas monoclonal
MORT1 domain of FADD/MORT1 as bait (Boldin et al.,antibody or IgG3 class anti-APO1 antibody that possess
1996). At the same time, a collaborative group, led bya tendency to aggregate function as potent agonists
Dixit and Peter, continued the biochemical characteriza-(Trauth et al., 1989; Yonehara et al., 1989). X-ray diffrac-
tion of molecules recruited to the activated Fas receptortion analysis of the TNFb–TNF receptor complex has
(Muzio et al., 1996). Both groups identified the sameindicated that a TNFb trimer makes a complex with three
molecule, which was originally termed FLICE (FADD-molecules of the extracellular region of the TNF receptor
like ICE) or MACH (MORT1-associated CED-3 homo-(Banner et al., 1993), suggesting that TNF induces tri-
logue) and is now designated caspase-8 (Alnemri etmerization of the receptor. The similarity between the
al., 1996) (Table 1). Caspase-8 carries two DED/MORT1structures of FasL and TNF and between Fas and the
domains at the N-terminal region, through which it bindsTNF receptors suggests that FasL also induces trimeri-
FADD/MORT1. The C-terminal region of caspase-8 iszation of Fas and that the trimerized cytoplasmic region
then transduces the signal. related to ICE family members, more specifically, to
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Figure 1. Models for Apoptosis Signaling by Death Factors
(A) Fas-induced apoptosis. Binding of FasL to Fas induces trimerization of the Fas receptor, which recruits caspase-8 (FLICE/MACH) via an
adaptor, FADD/MORT1. The oligomerization of FLICE may result in self-activation of proteolytic activity and trigger the ICE protease cascade.
The activated ICE members can cleave various substrates, such as poly(ADP) ribose polymerase (PARP), lamin, rho-GDI, and actin, and cause
morphological changes to the cells and nuclei.
(B) TNF-induced apoptosis. TNF binds to TNFR1, and the trimerized receptor recruits TRADD via interactions between death domains. The
death domain of TRADD then recruits FADD/MORT1 in one pathway to activate caspase-8. In another pathway, RIP binds to TRADD and
transduces an apoptotic signal through the death domain. In addition, RIP together with TRAF2 activates NF-kB, which may induce the
expression of survival genes. The role of the kinase activity of RIP is currently unknown.
members of the caspase-3 (CPP32) subfamily, and re- self-activation of the protease domain. One apoptotic
pathway from TNFR1 uses caspase-8 pathway throughcombinant caspase-8 preferentially cleaves caspase-3
substrates over caspase-1 (ICE) substrates (Boldin et the interaction of TRADD with FADD/MORT1. TRADD
additionally recruits RIP, which may trigger a secondal., 1996).
Figure 1 presents the current model for Fas- and apoptotic pathway. The recently identified DR-3/Wsl-1
receptor is more similar to TNFR1 than to Fas. That is,TNFR1-mediated apoptosis. Binding of a trimeric FasL
to Fas induces trimerization of Fas, and FADD/MORT1 DR-3 binds TRADD, which then recruits FADD and RIP
(Chinnaiyan et al., 1996; Kiston et al., 1996). The apop-binds to the trimerized Fas cytoplasmic region through
the interaction of the respective death domains. Cas- totic signaling pathway downstream of RIP is currently
unknown. However, another death domain–containingpase-8 is then recruited to FADD/MORT1 through bind-
ing of the DED domains, which in turn may induce adaptor, termed RAIDD (RIP-associated Ich-1/CED-3
Table 1. Human ICE Protease Superfamily
Recognition
Proteases Alternative Names Sequence Substrates
caspase-1 ICE YVAD pro-IL1b, pro-caspase 3 and 4
caspase-4 ICErel-II, TX, ICH-2
caspase-5 ICErel-III, TY
caspase-2 ICH-1 PARP
caspase-9 ICE-LAP6 PARP
caspase-3 CPP32, Yama, apopain DEVD PARP, DNA-PK, SRE/BP, rho-GDI
caspase-6 Mch2 VEID lamin A
caspase-7 Mch3, ICE-LAP3, CMH-1 PARP, pro-caspase 6
caspase-8 FLICE, MACH, Mch5
caspase-9 ICE-LAP6, Mch6 PARP
caspase-10 Mch4
The caspase family members can be divided into three subfamilies: caspase-1 (ICE), caspase-2 (ICH-1), and caspase-3 (CPP32), according
to Alnemiri et al. (1996).
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homologous protein with a death domain) has recently designated as caspases (cysteine aspases) (Table 1)
(Alnemri et al., 1996). So far, recognition sequences forbeen identified (Duan and Dixit, 1997). RAIDD binds RIP
through its death domain and recruits caspase-2 (Ich-1) three ICE family members have been identified. That is,
caspase-1 (ICE) recognizes the sequence Tyr–Val–Ala–to RIP. Although an involvment of RAIDD in the TNFR1
or DR3/Wsl-1-mediated apoptotic pathway has not yet Asp (YVAD) in the proform of IL-1b, caspase-3 (CPP32/
Yama/apopain) recognizes Asp–Glu–Val-Asp (DEVD)been demonstrated, it is possible that RAIDD plays a
role in transducing an apoptotic signal from one of the and cleaves poly(ADP-ribose) polymerase, and cas-
pase-6 (Mch2) recognizes Val–Glu–Ile–Asp (VEID) anddeath receptors.
The signal from Fas seems to be restricted to cleaves lamin (Nicholson et al., 1995; Takahashi et al.,
1996). However, it is uncertain whether each ICE familyapoptosis, whereas other members of the TNF receptor
family including TNFR1 activate NF-kB. NF-kB activa- member has a specific substrate for mediating apop-
tosis, or if some members of the subfamily are redun-tion by TNF receptor family members is mediated by
TRAF (TNF receptor–associated factor) family (Rothe et dant, cleaving the same substrates. In this regard, it is
noteworthy that caspase-1-null mice do not show anyal., 1994). So far, five members have been identified in
this family, and all contain a TRAF domain of about 230 phenotype in programmed cell death (Li et al., 1995),
while the mice lacking caspase-3 show hyperplasia andamino acids. Among members of this family, TRAF2
binds directly to TNFR2 and CD30 and indirectly to disorganized cell development in the brain (Kuida et al.,
1996). These results suggest that caspase-1 is redun-TNFR1 through TRADD and RIP. A dominant-negative
TRAF2 blocks TNF-induced NF-kB activation, but not dant in all cell types, while caspase-3 plays a major role
in apoptosis in some cells of the brain.apoptosis (Liu et al., 1996). Instead, blocking NF-kB
activation with the dominant-negative TRAF2 potenti- Using what was known about the specific recognition
sequences of the ICE proteases, specific competitiveates the cytotoxic activity of TNF in various cell types,
suggesting that NF-kB activation leads to the expres- inhibitors and fluorescent substrates for caspase-1
and -3 have been designed (Thornberry et al., 1992). Insion of a protein(s) that inhibits TNF-induced cytotoxic-
ity. NF-kB consists of two subunits (p50 and p65) and addition, several proteins encoded by viral genes are
known to inhibit members of the ICE family. These in-exists in a complex with IkB in resting cells. The signal
from TRAF2 results in phosphorylation of IkB and subse- clude crmA, a cytokine response–modifier gene en-
coded by cowpox virus, and p35, coded for by Baculovi-quent degradation by the proteosome. NF-kB, thus re-
leased from IkB, enters the nucleus and activates vari- rus. These viral proteins seem to inhibit protease activity
by forming a stable complex. p35 has a broader specific-ous genes carrying the NF-kB response element. Cells
lacking one component of NF-kB (65 kDa) or expressing ity for ICE family members than crmA. That is, crmA
preferentially inhibits caspase-1 over caspase-3, whileIkB mutants that cannot be phosphorylated are more
sensitive to TNF-induced cytotoxicity, confirming that p35 inhibits both caspase-1 and -3 equally well.
Inhibitors of caspase-1 or -3 block Fas- and TNF-one of the target genes for NF-kB is a gene encoding
a survival factor (Beg and Baltimore, 1996; Liu et al., induced apoptosis, which suggests that both cas-
pase-1- and caspase-3-like proteases are involved in1996; Van Antwerp et al., 1996; Wang et al., 1996). These
results are in good agreement with the fact that Fas, Fas- and TNFR1- mediated apoptosis (Enari et al.,
1995b; Los et al., 1995; Tewari and Dixit, 1995; Enari etwhich cannot activate NF-kB,mediates a stronger apop-
totic signal than TNFR1, which can activate NF-kB. The al., 1996). Monitoring the protease activity with specific
fluorescent substrates for caspase-1 and -3 demon-cytotoxicity of TNF can be potentiated by cycloheximide
or actinomycin D, which is probably due to the inhibition strates that a caspase-1-like protease is transiently acti-
vated, whereas the activation of a caspase-3-like prote-of the NF-kB-induced gene expression.
ICE Protease Cascade ase gradually increases during Fas-induced apoptosis
(Enari et al., 1996). A similar sequential activation ofGenetic analysis of programmed cell death in C. elegans
has revealed a number of gene products that regulate caspase-1- and caspase-3-like proteases was also
found in vivo. When agonistic anti-Fas antibody wasthe cell death process (Ellis et al., 1991). Among them,
the CED-3 product is required for cell death, and molec- administered to mice, the livers were damaged (Oga-
sawara et al., 1993). As the damage proceeded, cas-ular cloning of the ced-3 gene revealed it to be a homo-
logue of mammalian ICE (interleukin-1b converting en- pase-1-like activity was detected in the liver, followed
by the gradual activation of a caspase-3-like proteasezyme) (Yuan et al., 1993), which converts the IL-1b
precursor to the mature form. ICE is a cysteine protease (Rodriguez et al., 1996a). The activation of the caspase-
3-like protease is dependent on the activation of a cas-consisting of two large (p17) and two small (p10) sub-
units, which are generated by proteolytic cleavage of pase-1-like protease (Enari et al., 1996), indicating that
these proteasesare sequentially activated.This sequen-the ICE precursor (a zymogen). Cross-hybridization with
ICE cDNA and a search of the human genome database tial activation can also be seen in a cell-free system.
That is, cell lysate from Fas-activated, but not fromrevealed at least 10 ICE homologues (see Table 1), which
are divided into three subgroups (ICE-like, CPP32-like, nonactivated cells, induced apoptotic morphological
changes in intact nuclei (Enari et al., 1995a). However,and Ich1-like proteases), based on their sequence ho-
mology (Alnemri et al., 1996). All of these cause apop- when the cell lysates from growing, nonapoptotic cells
were supplemented with recombinant caspase-1 or -3,tosis when overexpressed in cells. They appear to be
cysteine proteases, containing conserved sequences the lysates induced apoptosis. This caspase-1-induced
apoptosis was inhibited, not only by an inhibitor of cas-for substrate binding and catalysis; they cleave their
substrates after aspartic acid. Therefore, they are now pase-1, but also by the inhibitor of caspase-3 (Enari et
Review: Apoptosis by Death Factor
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al., 1996), confirming the sequential activation of cas- However, little is known about the biochemical mecha-
pase-1- and caspase-3-like proteases. It is likely that nism whereby CED-9/Bcl-2 and their family members
other members of the ICE family are also activated in inhibit apoptosis. Bcl-2 and Bcl-x are localized to outer
the cascade, cleaving their “death substrates” such as mitochondrial membranes and endoplasmic reticulum
lamin, actin, poly(ADP)ribose polymerase, rho-GDI, as well as nuclear membranes. The tertiary structure of
SREBP, and DNA-dependent protein kinase, to cause Bcl-xL has been determined by X-ray and NMR analyses
the apoptotic morphological changes observed on cells (Muchmore et al., 1996). It consists of two central, hy-
and nuclei, as well as chromosomal DNA degradation. drophobic a helices, which are similar to the pore-form-
As discussed above, Fas engagement recruits cas- ing bacteria toxins such as diphtheria toxin and the
pase-8 to the Fas receptor complex. How can this result colicins, suggesting that Bcl-xL also generates pores in
be integrated into the model of sequential ICE protease the membrane. When mitochondria are damaged by an
activation? Here, I suggest two models. In the first agent that causes permeability transition, nuclear apop-
model, the oligomerization of caspase-8 through the tosis is induced (Zamzami et al., 1996). This permeability
interaction with FADD/MORT1 leads to its autocatalytic transition of mitochondrial membrane, and thus nuclear
activation, which then triggers the protease cascade by apoptosis, is blocked by Bcl-2, suggesting that the
cleaving the caspase-1-like protease zymogen. In the membrane pores in the mitochondria, generated by
second model, oligomerization does not activate cas- the Bcl-2 family members, play an important role in
pase-8, but a caspase-1-like protease activates the apoptosis, at least in this system.
oligomerized caspase-8, which then sequentially acti- Bcl-2 and Bcl-xL can also inhibit Fas-mediated apop-
vates other members of the ICE family. In addition to tosis in vitro as well as in vivo (Itoh et al., 1993; Boise
ICE family proteases, other proteases such as cathepsin et al., 1995; Rodriguez et al., 1996b). Fas activation dam-
D aspartic protease and the serine protease AP24 ages mitochondrial function, but the damage is inhibited
(apoptosis protease 24) may be involved in Fas- and by ICE protease inhibitors (Krippner et al., 1996). These
TNFR1-induced apoptosis. To understand how these results suggest that the mitochondrial damage is down-
proteases may be involved in the apoptotic process, stream of the ICE protease cascade in Fas-induced
it will be necessary to biochemically characterize the apoptosis and is probably a secondary effect. Thus, it
purified or recombinant proteins and determine their is not clear how Bcl-2/Bcl-xL located in mitochondria
specific substrates.
can modulate the Fas-inducedapoptotic signaling path-
The Bcl-2 Family
way that seems to take place in the cytoplasm. One
ced-9, a homologue of the mammalian protooncogene
possible mechanism is that the damage of mitochondria
Bcl-2, prevents programmed cell death in C. elegans
by ICE protease may amplify the signal by releasing
(Hengartner and Horvitz, 1994). Similarly, overexpres-
apoptosis-inducing molecules (Krippner et al., 1996;
sion of Bcl-2 blocks apoptosis of mammalian cells that
Zamzami et al., 1996).is triggered by a number of different stimuli such as
Other Regulators in the Signaling Pathwayfactor deprivation, irradiation, c-myc, or anti-cancer
Ceramide, generated by sphingomyelinases, increasesdrugs. A number of CED-9/Bcl-2 family members have
during Fas- or TNFR1-mediated apoptosis, and cera-been identified in mammals: Bcl-2, Bcl-xL, Bcl-w, and
mide itself can induce cell death (Spiegel et al., 1996).Mcl-1 inhibit apoptosis, whereas others, such as Bax,
Since ceramide activates the ras/MAP kinase pathway,Bik, Bak, Bad, and Bcl-xs, activate apoptosis. The vari-
it was postulated that activated ras is responsible forous Bcl-2 family members can dimerize with one an-
apoptotic cell death. However, the recent observationother, with one monomer antagonizing or enhancing the
that generation of ceramideand activation of JNKduringfunction of the other. In this way, the ratio of inhibitors
Fas activation is blocked by ICE protease inhibitors sug-to activators in a cell may determine the propensity of
gests that the production of ceramide occurs down-the cell to undergo apoptosis (Yang and Korsmeyer,
stream of the ICE protease cascade (Gamen et al., 1996;1996). For example, if either bcl-x (Motoyama et al.,
Lenczowski et al., 1997). An increase in ceramide during1995) or bcl-2 (Veis et al., 1993) is disrupted in mice, the
Fas activation is likely to be one of the changes thatanimals die as embryos or postnatally, respectively, as
accompanies apoptosis and is unlikely to be a mediatorthe result of excessive programmed cell death in partic-
of apoptosis. Many other proteins have been suggestedular organs. Conversely, if bax is disrupted, some normal
as regulators of Fas-mediated apoptosis. For example,programmed cell death fails to occur (Knudson et al.,
c-abl tyrosine kinase, FAP tyrosine phosphatase, and1995). Another attractive mechanism to regulate dimer-
small stress proteins (HSP24) inhibit the process,ization of Bcl-2 family members is phosphorylation (Ga-
whereas the Fas-associated proteins of p59fyn kinasejewski and Thompson, 1996). For example, Bad, a pro-
and FAF seem to augment apoptotic signal induced byapoptotic member of the Bcl-2 family, is phosphorylated
Fas. How these proteins regulate the process is currentlyby a putative kinase that can be activated by growth
unknown.factor engagement. The phosphorylated Bad loses the
ability to bind Bcl-xL. Instead, it binds to 14-3-3, a pro-
tein that can interact with several signaling enzymes.
Physiological and Pathological Roles of FasThe Bcl-xL dissociated from Bad now can execute its
Down-Regulation of the Immune Reactionantiapoptotic function (Zha et al., 1996).
Apoptosis occurs in various processes in mammalianHow does Bcl-2 or Bcl-xL inhibit apoptosis? Genetic
life (Jacobson et al., 1997). What kinds of apoptosisstudies of ced-9, ced-4, and ced-3 mutants in C. elegans
are regulated by the Fas system? Fas is ubiquitouslyindicate that ced-9 controls programmed cell death up-
stream of ced-4 and ced-3 (Shaham and Horvitz, 1996). expressed in various tissues with abundant expression
Cell
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after the activated T cells accomplish their task, they
must be removed to avoid accumulation. Mature T cells
from lpr or gld mice do not die after activation, and
activated cells accumulate in the lymph nodes and
spleens of these mice. When T cell hybridomas are acti-
vated in the presence of a Fas-neutralizing molecule,
they do not die. These results indicate that Fas is in-
volved in activation-induced suicide of T cells, i.e., in
down-regulation of the immune reaction (Figure 3A) (Na-
gata and Golstein, 1995). Peripheral clonal deletion may
also be mediated by the Fas system, because the cells
to be deleted in this process are activated by interac-
tions with cells expressing self antigens. However, thy-
mic clonal deletion is apparently normal in mice lacking
the functional Fas system (lpr-, gld-, or Fas-null mice)
(Singer and Abbas, 1994), even though thymocytes
abundantly express Fas and are sensitive to Fas-
induced apoptosis. These results suggest that Fas is
not involved in the deletion process in the thymus, al-
though one cannot rule out the possibility that this pro-
cess is mediated by redundant mechanisms.
In addition to T cells, the Fas-deficient mice accumu-
late B cells and have elevated levels of immunoglobulins
Figure 2. When Apoptosis Fails
of various classes that include anti-ssDNA and anti-
Wild-type (1/1) and Fas-null (2/2) mice were killed at 16 weeks of
dsDNA antibodies (Cohen and Eisenberg, 1991), sug-age, and their lymph nodes (LN) and spleen (SP) are shown (from
gesting an involvement of the Fas system in the deletionAdachi et al., 1995).
of activated or autoreactive B lymphocytes. In fact, im-
munization of mice with antigens rapidly induces Fas
in the thymus, liver, heart, and kidney. On the other expression in germinal centers. Furthermore, the acti-
hand, FasL is predominantly expressed in activated T vation of naive B cells through CD40 sensitizes them
lymphocytes and Natural Killer (NK) cells, although it to Fas-mediated apoptosis, while their costimulation
is also expressed constitutively in the tissues of the through CD40 and Ig receptor makes them resistant
“immune-privilege sites” such as the testis and eye, as (Rothstein et al., 1995). Although these results suggest
described below. The mouse mutations, lpr (lympho- that FasL-expressing T cells kill the Fas-expressing acti-
proliferation) and gld (generalized lymphoproliferative vated B cells, the precise mechanism and physiological
disease), are spontaneous recessive mutations (Cohen role of Fas in the deletion of B cells remains to be
and Eisenberg, 1991). Mice carrying homozygous muta- studied.
tions in lpr or gld develop lymphadenopathy and spleno- Children carrying a defect in the Fas gene have also
megaly by accumulating CD42CD82 cells of T cell origin, been identified (Fisher et al., 1995; Rieux-Laucat et al.,
and some strains of mice develop autoimmune dis- 1995). Most of these patients carry a heterozygous mu-
eases. Genetic and molecular analyses of lpr and gld tation in the Fas gene. The affected Fas protein seems
mutations showed that they are loss-of-function muta- to work in a dominant-negative fashion, and T cells from
tions in the Fas and FasL genes, respectively (Wata- the patients do not die upon activation. The patients
nabe-Fukunaga et al., 1992; Takahashi et al., 1994). The show phenotypes (ALPS, autoimmune lymphoprolifera-
Fas-null mice, established by gene targeting (Adachi et tive syndrome) that are remarkably similar to those of lpr
al., 1995), also show lymphadenopathy and splenomeg- mice, including lymphadenopathy, splenomegaly, and
aly (Figure 2), which is much more pronounced than in hypergammaglobulinemia. Some patients show autoim-
mice carrying the leaky lpr mutation. Furthermore, when mune diseases such as hemolytic anemia, thrombocyto-
Fas was expressed in the lymphocytes of lpr mice as a penia, and neutropenia by producing autoantibodies
transgene, the lymphoproliferative phenotype was res- against red blood cells and platelets. On the other hand,
cued (Wu et al., 1994), confirming that Fas plays a role the fathers or mothers of the patients, who also carry
in the programmed cell death of T lymphocytes. the heterozygous mutation of the Fas gene, do not show
T lymphocytes, which are responsible for removing an abnormal phenotype, suggesting that the patients
virally infected and cancerous cells, die at various carry mutations in other complementing genes. Alterna-
stages of their development. Most immature T cells are tively, Fas could berequired only for the perinatal period,
useless (incorrect rearrangement of the T cell receptor) and the parents may also have had a similar phenotype
or potentially detrimental (self-reactive) to the organism. in childhood that was rescued later, since the heterozy-
More than 95% of thymocytes that immigrate into the gous mutation is leaky.
thymus are eliminated by positive and negative selection Effector of Cytotoxic T Lymphocytes
during their development. In the periphery, mature T and Natural Killer Cells
cells that recognize self antigens are also deleted (pe- Cytotoxic T lymphocytes (CTL) recognize and kill cells
ripheral clonal deletion). When mature T cells encounter infected by viruses or bacteria, while NK cells kill cancer-
ous cells. The professional CTL are CD81 T cells, buttarget cells, they are activated to proliferate. However,
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Figure 3. Three Types of Killing by the Fas and FasL System
(A) Activation-induced suicide of T cells. Mature T lymphocytes are activated by T cell–receptor interaction with antigen-presenting cells. The
activated T cells express FasL, which binds to the Fas-expressing activated T cells to induce apoptosis.
(B) CTL-mediated killing of target cells. Virally infected cells present viral antigen as a complex with MHC. The cytotoxic T cells recognize
the antigen and become activated, leading to the expression of FasL. FasL then binds to Fas on the target cells to induce apoptosis.
(C) Killing of inflammatory cells in immune privilege sites and killing of CTL by tumor cells. Stromal cells in the immune privilege sites such
as the eye and testis and some tumor cells constitutively express FasL. When activated T cells or neutrophils enter an immune privileged
site, FasL binds to Fas on these cells and kills them to prevent inflammation. Similarly, when CTL or NK cells approach tumor cells, the tumor
cells counterattack these cells to escape from the immune destruction.
Th1-type CD41 T cells also showcytotoxicity. How these effector cells binds to Fas on the target cell and causes
apoptosis by activating caspases, as described aboveCTL and NK cells kill target cells was under debate for
a long time, because a well-known perforin/granzyme- (Figure 3B). A similar activation of CTLs through T cell
receptor would release perforins and granzymes thatbased mechanism could not account for all of the exam-
ples of CTL killing. However, the identification of FasL were stored in granules. It is believed that perforin
makes pores in the plasmamembrane of the target cells,as a cytotoxic molecule expressed by activated T cells
resolved this problem. Studies with mice deficient in through which granzymes are introduced. One of the
granzymes (granzyme B) is a serine protease aspase,either perforin/granzyme or FasL indicated that the per-
forin/granzyme and FasL systems are major pathways which activates some of the caspase family members
by proteolysis (Darmon et al., 1995). Thus, although per-for CTL-mediated cytotoxicity (Nagata and Golstein,
1995). Activation of CTLs through T cell–receptor inter- forin/granzyme and FasL can independently trigger the
cell death program, the processes leading to apoptosisaction with viral antigens induces the expression of the
FasL gene. The FasL expressed on the surface of the are similar in both cases. The CD81 T cells and NK cells
Cell
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use both the perforin/granzyme and FasL/Fas pathways, Fas gene are not tumorigenic. However, the families of
these patients sometimes have histories of Hodgkin’swhereas the Th1-type CD4 T cells preferentially use the
FasL system. Whether particular CD81 T cells and NK lymphoma (Fisher et al., 1995). The abnormal survival
of the lymphocytes may allow the cells to accumulatecells have any preference for using the perforin/gran-
zyme or FasL/Fas system on specific target cells re- mutations that lead to malignancy. Genes for death fac-
tors and their receptors, such as FasL and Fas, maymains to bestudied. Furthermore, CTLs in mice deficient
in both the perforin and FasL systems show some resid- therefore be regarded as tumor suppressor genes. On
the other hand, when the system overfunctions, itual cytotoxicity in long-term assays (Braun et al., 1996),
suggesting that yetanother death factor(s), perhaps TNF causes tissue destruction and kills the animals. When
an agonistic anti-Fas antibody or recombinant FasL wasor TRAIL, functions as a CTL effector under these condi-
tions. injected into mice to activate the Fas system in vivo, the
mice were quickly killed by liver failure with symptomsImmune Privilege
Cellular immune response reactions and their associ- similar to fulminant human hepatitis (Ogasawara et al.,
1993; Tanaka et al., 1997). Fulminant hepatitis is knownated inflammatory responses can cause nonspecific
damage to nearby tissues. Although most organs can to be caused by abnormally activated T cells, and the
transformation of hepatocytes with hepatitis B virus ortolerate such inflammation, some, such as the eye and
testis, cannot. These organs, therefore, have a mecha- hepatitis C virus causes theup-regulation of Fas expres-
sion. These results suggest that under normal circum-nism to protect themselves against dangerous and un-
wanted immune reactions. These organs are called “im- stances, CTLs recognizing viral antigens expressed on
the cell surface of infected hepatocytes are activatedmune privilege sites” and are able to support allogenic
and xenogeneic tissue transplants. Initially, it was through the T cell receptor and kill the hepatocytes via
the Fas/FasL system. If this killing process works prop-thought that immune privilege is maintained by pre-
venting the activated cells from entering the organs. erly, it benefits the organism. However, when thesystem
is exaggerated, it may lead to fulminant hepatitis. It isHowever, another attractive mechanism has recently
been proposed (Bellgrau et al., 1995; Griffith et al., 1995). possible that other CTL-induced autoimmune diseases
such as graft-versus-host disease, AIDS, and insulitisThat is, although the activated inflammatory cells can
enter these organs, they are immediately killed by FasL are also mediated by the Fas system.
Various cancer patients produce TNFa in a solubleexpressed in the organs (Figure 3C). The constitutive
expression of functional FasL has been found in the form, and it works like a cachectin to induce systemic
tissue damage. Similarly, the soluble form of FasL wascorneal epithelium and endothelium, iris, and ciliarycells
of the eye, as well as in the Sertoli cells of the testis. found in the sera of patients with NK lymphoma or large
granular lymphocytic leukemia (LGL) of the NK or T cellWhen the eyes of wild-type mice were infected with
herpes simplex virus (HSV-1), very few inflammatory type (Tanaka et al., 1996). The leukemic cells themselves
were found to express functional FasL on their surfaces.cells were found associated with the retina, while mas-
sive inflammation was observed in the retina of gld mice, These patients often show systemic tissue damage such
as hepatitis and neutropenia. Since hepatocytes andwhich have a defect in FasL. Furthermore, while testes
expressing functional FasL survived when transplanted neutrophils are particularly sensitive to Fas-mediated
apoptosis, it is possible that the systemic tissue damageunder the kidney capsule of allogenic animals, testis
grafts from gld mice were rejected. These findings indi- observed in these patients is due to FasL in their serum
or to FasL expressed on the circulating leukemic cells.cate that FasL accounts for at least part of the immune-
privileged nature of the eye and testis and suggest a
use for FasL as an immunosuppressive agent to target
Conclusions and Perspectivesactivated effector cells in transplantation. In fact, when
islets of Langerhans were cotransplanted with synge-
Many growth and differentiation factors regulate prolif-neic myoblasts expressing functional FasL, they were
eration and differentiation of mammalian cells duringprotected from immune rejection and were able to main-
development. So far, three death factors (TNF, FasL,tain normoglycemia for a substantial period in a mouse
and TRAIL) and four death factor receptors (Fas, TNFR1,model system for diabetes (Lau et al., 1996). Similarly,
DR3/Wsl-1, and CAR1) have been identified. Loss-of-several groups have recently found that some tumor
function mutations in the Fas system, lpr and gld mice,cells become resistant to Fas-induced apoptosis and
illustrated the importance of this death factor system inconstitutively express FasL (Hahne et al., 1996; Strand
maintaining mammalian homeostasis, specifically in theet al., 1996). FasL expressed on tumor cells then coun-
life and death of lymphocytes. It is possible that manyterattacks CTL and NK cells by binding Fas on their
more death factor and receptor systems that regulatesurfaces to cause apoptosis. This mechanism may also
apoptosis in a tissue-specific manner will be found inaccount for the ability of tumor cells to evade immune
the future. Growth and differentiation signals are medi-destruction.
ated by the phosphorylation and dephosphorylation ofA Double-Edged Sword
proteins, as well as by small second-messenger mole-As long as death factors are appropriately expressed,
cules such as cAMP and phosphatidyl inositol. Thesethey will be useful in maintaining homeostasis. However,
signals are reversible in most cases. On the other hand,if thesystem under-or over-functions, it will have delete-
the apoptosis signal triggered by death factors is irre-rious effects. Loss of function causes hyperplasia, such
versible; that is, a protease cascade is activated by theas lymphoproliferation. The lymphocytes accumulated
in patients carrying the heterozygous mutation in the death signal, and the proteases cleave various cellular
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